Ye Weiguo, Chief Operating Officer of Gyre Therapeutics, reported stock sales on May 20 and 21, 2026, totaling $136,653, according to an SEC Form 4 filing.
On May 20, he sold 9,400 shares at a weighted average price of $6.15 per share (range $6.0908-$6.2935). The next day, he sold another 12,820 shares at the same average price (range $6.05-$6.22).
Before the sales, Ye acquired 22,220 shares by exercising fully vested stock options at $0.75 per share, totaling $16,665. The options expire on October 31, 2030.
After transactions, Ye directly holds 700,000 shares. GYRE stock trades near its 52-week low of $5.97, down 7.5% over the past week and 46% over the past year. Bond.az analysis suggests the stock appears slightly overvalued. The company has negative EPS of $0.08 but maintains a strong balance sheet with a current ratio of 4.64. Analysts project a price target of $18-20, though sales are expected to decline 13% this year.
In recent news, Gyre Therapeutics submitted a New Drug Application for F351 to China's NMPA for liver fibrosis. It also completed the acquisition of Cullgen Inc. in a stock deal worth $300 million. Dr. Ying Luo, formerly of Cullgen, has become CEO. The F351 application received priority review status. H.C. Wainwright reiterated a Buy rating with a $18 price target.
